Investigation of the HSPG2Gene in tardive dyskinesia-new data and meta-analysis

Clement C. Zai, Frankie H. Lee, Arun K. Tiwari, Justin Y. Lu, Vincenzo De Luca, Miriam S. Maes, Deanna Herbert, Anashe Shahmirian, Sheraz Y. Cheema, Gwyneth C. Zai, Anupama Atukuri, Michael Sherman, Sajid A. Shaikh, Maria Tampakeras, Natalie Freeman, Nicole King, Daniel J. Müller, Lior Greenbaum, Bernard Lerer, Aristotle N. VoineskosSteven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Gary Remington, James L. Kennedy

Research output: Contribution to journalArticlepeer-review

Abstract

Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however, genetic factors play an important role. The Perlecan (HSPG2) gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. To add to the evidence for this gene in TD, we conducted a meta-analysis specific to the relationship of HSPG2 rs2445142 with TD occurrence, while also adding our unpublished genotype data. Overall, we found a significant association of the G allele with TD occurrence (p = 0.0001); however, much of the effect appeared to originate from the discovery dataset. Nonetheless, most study samples exhibit the same trend of association with TD for the G allele. Our findings encourage further genetic and molecular studies of HSPG2 in TD.

Original languageEnglish
Article number974
JournalFrontiers in Pharmacology
Volume9
Issue numberSEP
DOIs
StatePublished - 18 Sep 2018

Keywords

  • Meta-analysis
  • Perlecan/heparan sulfate proteoglycan 2 (HSPG2)
  • Pharmacogenetics
  • Schizophrenia
  • Tardive dyskinesia

Fingerprint

Dive into the research topics of 'Investigation of the HSPG2Gene in tardive dyskinesia-new data and meta-analysis'. Together they form a unique fingerprint.

Cite this